Everolimus - CAS 159351-69-6
Catalog number: 159351-69-6
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) with an immunosuppressive activity which is comparable to that of rapamycin. It inhibits cytokine-mediated lymphocyte proliferation. Everolimus can be used as an immunosuppressant in the treatment of renal cell cancer and other cancers.
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
inhibitor of mTOR, immunosuppressant
Off-White to Pale Yellow Solid
Afinitor; Certican; Zortress; RAD001; SDZ-RAD; 40-O-(2-Hydroxyethyl)rapamycin; 42-O-(2-Hydroxy)ethyl Rapamycin
Soluble in ethanol, methanol, DMF or DMSO. Limited water solubility.
Shelf Life:
2 years
Melting Point:
107-113 °C
Canonical SMILES:
1. Structure guided design of improved anti-proliferative rapalogs through biosynthetic medicinal chemistry
Matthew A. Gregory, Andrew L. Kaja, Barrie Wilkinson*. Chem. Sci., 2013, 4, 1046–1052
Rapamycin is a polyketide natural product produced by Streptomyces rapamycinicus NRRL5491. The intracellular receptor of 1 is the 12 kDa FK506 binding protein,(FKBP12). The 1–FKBP12 complex is a highly selective and potent inhibitor of mammalian/mechanistic target of rapamy- cin complex 1 (mTORC1) at sub-nanomolar concentrations. Rapamycin is used clinically as an immunosuppressant after organ transplantation (Rapamune) and for the prevention of restenosis after stent insertion for the treatment of coronary heart disease (e.g. Cypher).Semi-synthetic derivatives of Rapamycin including temsirolimus (Torisel) and everolimus (Afinitor) are both approved for the treatment of renal cell carcinoma and other proliferative diseases. Further rapamycin analogues (rapalogs) have shown potential for the treatment of cardiovascular, autoimmune and neurodegenerative diseases.
2. Biosynthetic medicinal chemistry of natural product drugs
Frank E. Koehn*. Med. Chem. Commun., 2012, 3, 854–865
Rapamycin (sirolimus) is a 31-membered macrocyclic polyketide produced by Streptomyces hygroscopicus. It was discovered on the basis of its antifungal activity and then soon was shown to have potent anti-proliferative/immunosuppressive effects. Rapamycin and its analogues exert their antiproliferative effect by inhibition of mTOR (mammalian target of rapamycin) via FKBP-12-mediated formation of a ternary complex. The powerful anti-proliferative activity of rapamycin have been harnessed clinically to treat organ transplant rejection, and further development has furnished three semisynthetic analogues- temsirolimus (2) and everolimus (34) which are both approved for treatment of advanced renal cancer, and ridaforolimus (35) which is in late stage clinical trial for the treatment of metastatic soft-tissue and bone cancer. (Fig. 6) In contrast to FK506, rapamycin has been the subject of considerable biosynthetic medicinal investigation, and serves as a good example of what is possible with modular polyketide systems.
3. The metamorphosis of vascular stents: passive structures to smart devices
Purandhi Roopmani, Swaminathan Sethuraman, Santhosh Satheesh and Uma Maheswari Krishnan*. RSC Adv.,2016, 6,2835–2853
The initial success with sirolimus had triggered a search of sirolimus analogues that possess similar anti-proliferative effect but lesser adverse effects. Among these analogues, everolimus (a new macrocylic triene derivative), biolimus A9, immunosuppressive agents such as cyclosporine, mycophenolic acid and tacrolimus, which induce G1 arrest leading to reduced proliferation and immune response, have been incorporated in stents. Everolimus is a macrolide antibiotic that possesses the ability to suppress the immune response and cell proliferation leading to prevention of restenosis similar to sirolimus. It possesses greater polarity than sirolimus and hence has better bioavailability and is rapidly absorbed on the arterial wall and attains peak concentration within few hours thereby offering better efficacy. Experimental data have shown that orally administered everolimus inhibits in-stent neointimal formation and significantly promotes neointimal healing. Evorolimus has been found to act at a later stage than the calcineurin inhibitor cyclosporin and tacrolimus.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mTOR Products

CAS 1028385-32-1 BEZ235 Tosylate

BEZ235 Tosylate
(CAS: 1028385-32-1)

BEZ235 tosylate is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assay...

CAS 154447-38-8 LY 303511

LY 303511
(CAS: 154447-38-8)

PI3K inhibitory activity. Inhibits voltage-gated Kv channel activity (IC50 = 64.6 μM). Various pharmacological effects including inhibition of LPS-stimulated FP...

CAS 326914-06-1 MHY1485

(CAS: 326914-06-1)

mTOR activator with an inhibitory effect on autophagy. MHY1485 markedly increased the LC3II/LC3I ratio dose-dependently and time-dependently by inhibition of th...

CAS 159351-69-6 Everolimus

(CAS: 159351-69-6)

Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) with an immunosuppressive activity which is comparable to that of rapamycin. It inhibits cyto...

CAS 1394076-92-6 GNE-317

(CAS: 1394076-92-6)

GNE-317 is a potent and selective PI3K inhibitor with potential anticncer activity. GNE-317 targets the PI3K pathway and can cross the Blood–Brain Barrier. GNE-...

CAS 1032754-93-0 Apitolisib

(CAS: 1032754-93-0)

Apitolisib, also known as GDC-0980 and RG7422;  or GNE390, is a dual PI3 kinase/mTOR inhibitor,   is also an orally available agent targeting phosphatidylinosit...

CAS 1429639-50-8 CZ415

(CAS: 1429639-50-8)

CZ415 is a highly selective potent mTOR inhibitor with little activity on other lipid and protein kinases with efficacy in a collagen induced arthritis model an...

CAS 1222998-36-8 Torin 1

Torin 1
(CAS: 1222998-36-8)

Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively.

CAS 1224844-38-5 MLN0128

(CAS: 1224844-38-5)

MLN0128, also known as INK128, is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR co...

CAS 936890-98-1 OSI-027

(CAS: 936890-98-1)

mTOR kinase inhibitor OSI-027 is an orally bioavailable mammalian target of rapamycin (mTOR) kinase inhibitor with potential antineoplastic activity. mTOR kinas...

CAS 934493-76-2 Voxtalisib (XL-765)

Voxtalisib (XL-765)
(CAS: 934493-76-2)

SAR245409 (XL765) is a potent and highly selective pan inhibitor of class I PI3Ks (α/β/γ/δ, IC50=39/110/9/43 nM) with activity against mTOR(IC50=160-910 nM).

CAS 1062161-90-3 WYE-687

(CAS: 1062161-90-3)

WYE-687 is a potent and ATP-competitive and selective inhibitor of mTOR with IC50 of 7 nM.

CAS 1033735-94-2 GNE-493

(CAS: 1033735-94-2)

GNE-493 is a potent, selective, and orally available dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/12/16/16/32 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ/mTOR respectively...

CAS 1207358-59-5 mTOR-IN-1

(CAS: 1207358-59-5)

Selective inhibitors of mammalian target of rapamycin (mTOR) kinase based upon saturated heterocycles fused to a pyrimidine core were designed and synthesized. ...

CAS 1092351-67-1 PP242

(CAS: 1092351-67-1)

PP242 is a novel potent and selective mTOR inhibitor with an IC50 of 8 nM. PP242 also shows residual (micromolar) activity against panel of tyrosine kinases. Bu...

CAS 6724-53-4 Perhexiline maleate salt

Perhexiline maleate salt
(CAS: 6724-53-4)

Perhexiline maleate salt is a carnitine palmitoyltransferase 1 (CPT1) and CPT2 inhibitor. It is an anti-anginal metabolic modulator and used in treatments for a...

CAS 1009298-09-2 AZD-8055

(CAS: 1009298-09-2)

AZD-8055 is an inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/t...

CC-115 hydrochloride
(CAS: 1300118-55-1)

The hydrochloride salt form of CC-115 which is a mTOR / DNA-PK inhibitor that probably has antineoplastic effect through influencing the cellular proliferation ...

CAS 1197160-78-3 Gedatolisib (PF-05212384, PKI-587)

Gedatolisib (PF-05212384, PKI-587)
(CAS: 1197160-78-3)

Gedatolisib (PF-05212384, PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Phase 2.

CAS 1246535-95-4 Desmethyl-VS-5584

(CAS: 1246535-95-4)

Desmethyl-VS-5584, a demethyl analogue of VS-5584, is a PI3K/mTOR kinase inhibitor for the treatment of cancer.

Chemical Structure

CAS 159351-69-6 Everolimus

Quick Inquiry

Verification code

Featured Items